AML + Importance of Minimal Residual Disease in Blood Cancers: New and Emerging Treatments
Presented at our 2021 New and Emerging Treatments Conference on November 10.
In this free virtual program for patients and caregivers, physician experts presented the latest advances in acute myeloid leukemia (AML) treatments and the importance of minimal residual disease in the management of blood cancers. The presentation is followed by a Q + A.
Anand Patel, MD, University of Chicago Medicine (presented on AML)
Celalettin Ustun, MD, Rush University Medical Center (presented on minimal residual disease in blood cancers)